CTLA4 and neoplasm: 48 tumor samples from patients treated with ICIs (35 anti-PD-1; 11 anti-CTLA4 + PD-1; and 2 anti-CTLA4) were profiled and two clusters of CD8 + T cells, associated with tumor progression or regression respectively, were identified.